A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer

Inclusion Criteria: * Male/Female patients aged 18 years or over * Patients must provide written informed consent * Life expectancy above 3 months * Patients willing to comply with treatment follow-up, and to accept a biopsy at day 29 after initiation of the treatment * Patients with histologically confirmed diagnosis of unresectable pancreatic adenocarcinoma with symptoms related to the primary tumor. Abraxane® plus Gemcitabine should be the appropriate standard of care to be administered. * ECOG Performance status 0 or 1 * Adequate baseline organ function (hematologic, liver, renal and nutritional) * Use a reliable method of contraception in fertile men and women Exclusion Criteria: * Active infection or other serious illness or autoimmune disease * Treatment with live attenuated vaccines in the last three weeks * Known chronic liver disease (liver cirrhosis, chronic hepatitis) * Treatment with another investigational agent within its five half-lives prior to VCN-01 infusion * Viral syndrome diagnosed during the two weeks before inclusion * Chronic immunosuppressive therapy * Known concurrent malignant hematologic or solid disease * Pregnancy or lactation. Patients must agree to use effective contraception or be surgically sterile. * Patients receiving full-dose anticoagulant / antiplatelet therapy * Patients with Li Fraumeni syndrome or with previous known retinoblastoma protein pathway germinal deficiency